Intranasal immunotherapy with NasoLeish® alone or in combination with miltefosine for treatment of murine visceral leishmaniasis

Key Points

• To evaluate the effectiveness of intranasal NasoLeish® and its combination with miltefosine in treating murine visceral leishmaniasis.
• Utilized intranasal administration for therapy
• Included assessments of immune response
• Conducted tests in murine models of visceral leishmaniasis.
• NasoLeish® showed a significant immune response increase in treated mice
• Combination therapy improved treatment outcomes over NasoLeish® alone.
• Miltefosine enhanced the overall efficacy without increasing side effects.